Two possible explanations for the decrease of serum prolactin in postmenopausal women after long-term raloxifene have been suggested by researchers in Italy.
This decrease may be either a direct antioestrogenic effect of raloxifene on lactotrope cells or an increase of opiatergic tone on the hypothalamic pituitary region, report Dr A Lasco and colleagues from the University of Messina, Messina.
Raloxifene hydrochloride is a selective oestrogen receptor modulator recently approved for prevention of osteoporosis. These authors sought to evaluate the effects of six-month treatment with this agent on serum gonadotropin and prolactin (PRL) levels and on TRH-stimulated PRL responsiveness in women who have not had oestrogen replacement therapy. Sixteen healthy postmenopausal women averaging in their early 50s, and with a menopausal age in the early 40s, were divided into two groups on the basis of their bone status as
evaluated by DXA at the lumbar level.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!